Poseida Therapeutics is a biopharmaceutical company that develops therapeutics for patients with high unmet medical needs. It is currently in the Phase I trial for several cancer treatment products including an autologous chimeric antigen receptor T-cell product for prostate cancer and an allogeneic off-the-shelf CAR-T product for multiple myeloma. The company also engages in the development of gene therapies and has a research collaboration and license agreement with a pharmaceutical company.